REGISTER NOW

Wednesday, June 10, 2026

10:00 am ET / 14:00 UTC

FEATURING:
Alex Cayley, PhD, Principal Scientist at Lhasa Limited
Pavlos Dimitriou, MSc, Business Partnerships Manager at Lhasa Limited

SUMMARYFor decades, carcinogenicity assessments have relied on traditional animal-based approaches that are increasingly recognised as slow, costly, resource-intensive, and poorly predictive of human outcomes. As regulatory frameworks evolve, most notably through the ICH S1B(R1) addendum, clear pathways are emerging to apply weight of evidence (WoE) approaches that can reduce or replace full carcinogenicity studies when scientifically justified. However, practical implementation and best practice around these approaches are still emerging and understanding how these methods can be accepted and operationalised is crucial to their acceptance. Building on successful use cases and worked examples, this webinar will illustrate how next generation carcinogenicity assessment approaches can be implemented in practice with New Approach Methodologies (NAMs) within pharmaceuticals and beyond.

The session will conclude with a demonstration of Kaptis, a Lhasa Limited AOP-driven decision support solution. Attendees will see how Kaptis organises carcinogenicity knowledge, supports WoE assessments, predicts ICH S1 classifications, and streamlines testing strategies to enable faster, more transparent, and more cost effective human safety decisions that are resilient to future regulatory and scientific developments.

Complete details for this training are available at https://www.pcrm.org/NAMSpotlight.

Available resources and materials from this webinar will be added to the NAM Spotlight portal and posted to NURA's On-Demand Catalog following the training.

Download as iCal file